Filing Flows › 10x Genomics (TXG) › R&D spending
10x Genomics (TXG) R&D spending by quarter
10x Genomics' R&D spending was $52.9M in Q3 2026 (third quarter 2026), -7% from Q1 2026. Over the last 4 quarters it ranged from $52.9M (Q3 2026) to $57.2M (Q3 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $52.9M | -7% | -7% |
| Q1 2026 | $56.8M | +2% | — |
| Q4 2025 | $56.0M | -2% | — |
| Q3 2025 | $57.2M | — | — |
Q3 2026 at a glance
10x Genomics, Q3 2026: revenue $151M (+1% year over year), operating margin -10.7%, net loss $19.4M, operating cash flow $15.8M. The chart follows the revenue to costs, profit and cash.
Questions
What is 10x Genomics' R&D spending?
10x Genomics' R&D spending was $52.9M in Q3 2026 (third quarter 2026), -7% from Q1 2026.
How has 10x Genomics' R&D spending changed?
Over the last 4 quarters it ranged from $52.9M (Q3 2026) to $57.2M (Q3 2025).